Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Stem cell transplantation for multiple myeloma.

Cristina Gasparetto1

  • 1Duke University Medical Center, Durham, NC 27710, USA. c.gasparetto@cgct.duke.edu

Cancer Control : Journal of the Moffitt Cancer Center
|March 17, 2004
PubMed
Summary

High-dose chemotherapy followed by stem cell transplant improves outcomes for multiple myeloma (MM) patients. Further research is needed to optimize this advanced MM treatment strategy.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrating Recent Evidence and Expert Perspectives Into the Management of Multiple Myeloma: Consensus Recommendations From the 2025 Bridging the Gaps Conference.

American journal of hematology·2026
Same author

Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms.

Bone marrow transplantation·2026
Same author

Impact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment.

Bone marrow transplantation·2026
Same author

Musculoskeletal Adverse Events Following BCMA CAR T-Cell Therapy in Multiple Myeloma: Clinical Characteristics and Immune Correlates.

Transplantation and cellular therapy·2026
Same author

Treatment of Relapsed/Refractory t(11;14) Multiple Myeloma and High-Risk Myelodysplastic Syndrome With Venetoclax.

Case reports in hematology·2025
Same author

Lower dose and weekly schedules of selinexor in multiple myeloma - updated evidence on safety and efficacy.

Frontiers in oncology·2025

Area of Science:

  • Hematologic Malignancies
  • Oncology
  • Stem Cell Transplantation

Background:

  • Multiple myeloma (MM) is a prevalent hematologic malignancy with a median survival of 5 years.
  • Curative treatment for MM remains challenging for most patients.
  • Current treatment strategies aim to improve patient outcomes and long-term survival.

Purpose of the Study:

  • To review current treatment strategies for multiple myeloma (MM).
  • To evaluate the efficacy of high-dose chemotherapy followed by stem cell transplantation.
  • To identify areas for improvement in MM treatment protocols.

Main Methods:

  • Literature review focused on MM treatment strategies.
  • Analysis of chemotherapy regimens, including high-dose therapy and stem cell transplantation.
  • Evaluation of complete response rates and overall survival.

Main Results:

  • High-dose chemotherapy followed by autologous stem cell transplantation yields higher complete response rates and improved long-term survival compared to standard chemotherapy.
  • The traditional melphalan and prednisone (MP) regimen has limited efficacy, with 50% of patients developing resistance.
  • Standard dose chemotherapy combinations have not significantly improved overall survival.

Conclusions:

  • Advances in autologous and allogeneic transplantation, anti-MM agents, and immunotherapy offer new possibilities for MM treatment.
  • Combining different therapeutic strategies may lead to synergistic responses in MM.
  • Optimizing induction therapy, stem cell collection, and high-dose therapy protocols is crucial for enhancing treatment efficacy.

Related Experiment Videos